The polypill reduces cardiovascular mortality by 33%, reveals SECURE

Dr. Valentín Fuster, Physician-in-Chief of The Mount Sinai Hospital

The polypill developed by the CNIC and Ferrer, which includes three drugs (aspirin, an angiotensin-converting enzyme (ACE) inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.

The polypill reduces mortality from cardiovascular causes in this population by 33% according to SECURE study, coordinated by the Spanish National Center for Cardiovascular Research (CNIC). The results were aired in a session at the European Society of Cardiology meeting (ESC 2022) in Barcelona and published in The New England Journal of Medicine (NEJM).

What were the executives’ thoughts on the findings?

Dr. Valentín Fuster, principal investigator of the SECURE study, CNIC General Director, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, said “The results show for the first time that the polypill achieves clinically relevant reductions in the recurrent cardiovascular events among people who have recovered from a previous heart attack.”

According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, “The 33% reduction in cardiovascular mortality shows the efficacy of treatment with Trinomia compared to standard treatment and it represents a vital step in our mission to provide significant and differential value to people who suffer from serious health conditions.”

What was the methodology of the study?

SECURE included 2499 patients from 7 countries (Spain, Italy, Germany, the Czech Republic, France, Poland, and Hungary) recovering after a myocardial infarction. The study participants were randomly assigned to receive standard therapy or the CNIC polypill. The average age of the participants was 76 years, and 31% were women. The study population included 77.9% with hypertension, 57.4% with diabetes, and 51.3% with a history of tobacco smoking.

The SECURE trial analyzed the incidence of four major cardiovascular events: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and emergency coronary revascularization (the restoration of blood flow through a blocked coronary artery).

The study followed patients for an average of 3 years and produced conclusive results: patients taking the polypill had a 24% lower risk of these four events than patients taking the three drugs separately. The standout finding of the study is the effect of the polypill on the key outcome of cardiovascular related death, which showed a relative reduction of 33%, from 71 patients in the group receiving standard treatment to just 48 in the polypill group.

The study found that patients in the polypill group had a higher level of treatment adherence than those in the control group, thus confirming the findings of the earlier FOCUS study.